Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: A double-blind, randomised, placebo-controlled trial

The Lancet Diabetes and Endocrinology

Volumn 2, Issue 12, 2014, Pages 944-953

  Ando, Katsuyuki ^a   Ohtsu, Hiroshi ^b   Uchida, Shunya ^c   Kaname, Shinya ^d   Arakawa, Yoshihiro ^a   Fujita, Toshiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c TEIKYO UNIVERSITY   (Japan)

^d KYORIN UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; POTASSIUM; ANTIHYPERTENSIVE AGENT; CREATININE; MINERALOCORTICOID ANTAGONIST; PROTECTIVE AGENT; SPIRONOLACTONE;

ADULT; AGED; ALBUMINURIA; ANTIALBUMINURIA ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIGESTIVE SYSTEM FUNCTION DISORDER; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; GLOMERULUS FILTRATION RATE; HEADACHE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERURICEMIA; JAPAN; LOW DRUG DOSE; MICTURITION; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SODIUM EXCRETION; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URINALYSIS; ANALOGS AND DERIVATIVES; COMPLICATION; FEMALE; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; URINE;

ADULT; AGED; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; CREATININE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PROTECTIVE AGENTS; RENAL INSUFFICIENCY, CHRONIC; SPIRONOLACTONE;

EID: 84933529443     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(14)70194-9     Document Type: Article

References (35)

1. Ihle BU, Whitworth JA, Shahinfar S, Cnaan A, Kincaid-Smith PS, Becker GJ Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. Am J Kidney Dis 1996, 27:489-495.
2. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997, 349:1857-1863. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
3. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet 1998, 352:1252-1256. on behalf of Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN).
4. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993, 329:1456-1462. for the Collaborative Study Group.
5. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004, 65:2309-2320.
6. Nagase M, Yoshida S, Shibata S, et al. Enhanced aldosterone signalingin the early nephropathy of rats with metabolic syndrome: possible contribution of fat derived factors. J Am Soc Nephrol 2006, 17:3438-3446.
7. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 2006, 47:1084-1093.
8. White WB, Duprez D, St Hillaire R, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003, 41:1021-1026.
9. Williams GH, Burgess E, Kolloch RE, et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 2004, 93:990-996.
10. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005, 28:2106-2112.
11. Sato A, Hayashi K, Naruse M, Saruta T Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003, 41:64-68.
12. Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006, 1:940-951.
13. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009, 20:2641-2650.
14. Yano Y, Hoshide S, Tamaki N, et al. Efficacy of eplerenone added to renin-angiotensin blockade in elderly hypertensive patients: the Jichi-Eplerenone Treatment (JET) study. J Renin Angiotensin Aldosterone Syst 2011, 12:340-347.
15. Ando K, Ohtsu H, Arakawa Y, et al. Rationale and design of the Eplerenone Combination Versus Conventional Agents to Lower Blood Pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertens Res 2010, 33:616-621.
16. Schulz KF, Altman DG, Moher D CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010, 152:726-732.
17. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009, 53:982-992.
18. Kawasaki T, Itoh K, Uezono K, Sasaki H A simple method for estimating 24 h urinary sodium and potassium excretion from second morning voiding urine specimen in adults. Clin Exp Pharmacol Physiol 1993, 20:7-14.
19. Hollenberg NK Aldosterone in the development and progression of renal injury. Kidney Int 2004, 66:1-9.
20. McCarron DA, Kazaks AG, Geerling JC, Stern JS, Graudal NA Normal range of human dietary sodium intake: a perspective based on 24-hour urinary sodium excretion worldwide. Am J Hypertens 2013, 26:1218-1223.
21. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001, 135:73-87.
22. Levey AS, Cattran D, Friedman A, et al. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2009, 54:205-226.
23. de Zeeuw D, Parekh R, Soman S CKD treatment: time to alter the focus to albuminuria?. Adv Chronic Kidney Dis 2011, 18:222-223.
24. Bomback A, Klemmer PJ The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007, 3:486-492.
25. Vegter S, Perna A, Postma MJ, Navis G, Remuzzi G, Ruggenenti P Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol 2012, 23:165-173.
26. Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008, 19:999-1007.
27. Shibata S, Mu S, Kawarazaki H, et al. Rac1 GTPase in rodent kidneys is essential or salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest 2011, 121:3233-3243.
28. Shibata S, Nagase M, Yoshida S, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med 2008, 14:1370-1376.
29. Fu Y, Hall JE, Lu D, et al. Aldosterone blunts tubuloglomerular feedback by activating macula densa mineralocorticoid receptors. Hypertension 2012, 59:599-606.
30. Epstein M Hyperkalemia as a constraint to therapy with combination renin-angiotensin system blockade: the elephant in the room. J Clin Hypertens 2009, 11:55-60.
31. Shavit L, Lifschitz MD, Epstein M Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. Kidney Int 2012, 81:955-968.
32. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013, 369:1892-1903.
33. Gaede P, Lund-Andersen H, Parving HH, Pedersen O Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.
34. Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH Enhanced renoprotective effects of ultra-high doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005, 68:1190-1198.
35. Mente A, O'Donnell MJ, Dagenais G, et al. Validation and comparison of three formulae to estimate sodium and potassium excretion from a single morning fasting urine compared to 24-h measures in 11 countries. J Hypertens 2014, 32:1005-1015.